CSIMarket
 
Cohbar Inc   (CWBR)
Other Ticker:  
 
 
Price: $0.7601 $-0.12 -13.625%
Day's High: $0.7601 Week Perf: -13.63 %
Day's Low: $ 0.76 30 Day Perf: -0.04 %
Volume (M): 3 52 Wk High: $ 3.59
Volume (M$): $ 2 52 Wk Avg: $1.88
Open: $0.76 52 Wk Low: $0.58



 Market Capitalization (Millions $) 2
 Shares Outstanding (Millions) 3
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -13
 Cash Flow (TTM) (Millions $) 3
 Capital Exp. (TTM) (Millions $) 0

Cohbar Inc
Cohbar Inc is a biotechnology company that specializes in the development of novel mitochondria-based therapeutics. The company's focus is on the discovery and development of mitochondria-derived peptides (MDPs) to address various age-related diseases such as fibrotic diseases, metabolic disorders, and neurodegenerative conditions. Cohbar Inc utilizes its proprietary technology platform to identify, optimize, and develop potential drug candidates. The company aims to provide innovative solutions that target the underlying causes of age-related diseases and improve patients' lives.


   Company Address: 1455 Adams Drive Menlo Park 94025 CA
   Company Phone Number: 446-7888   Stock Exchange / Ticker: NASDAQ CWBR
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Cohbar Inc

Cohbar Inc Reports Operating Loss of $-4.4 Million in Second Quarter of 2023; No Revenue Mentioned

As a reporter in the Major Pharmaceutical Preparations sector, I've spent today analyzing the second quarter financial results of Cohbar Inc. The company reported an operating loss of $-4.433349 million for the period from April to June 30, 2023. What's interesting is that no revenue has been mentioned in their financial reports for this period.
To truly understand the implications of this second quarter performance, it's important to put it into context. One way to do this is by comparing it to the same period in 2022, where Cohbar Inc recorded an operating loss of $-2.743685 million. While the increase in operating loss from 2022 to 2023 is significant, it is not entirely alarming.

Cohbar Inc

Cohbar Inc's Operating Shortfall Improves to $-3.251226 Million in Q1 2023, Generating Interest in Major Pharmaceutical Preparations Industry

Cohbar Inc is a smaller player in the Major Pharmaceutical Preparations industry, but it is starting to generate interest with its recent financial results. Even though the company posted an operating shortfall of $-2.300012 million in the first quarter of 2023, it has shown significant improvement compared to the first quarter of 2022. This news is important because Cohbar Inc is currently in the expansion cycle, and achieving efficiency is a vital aspect of growth.
Cohbar Inc is a biotechnology company that focuses on developing innovative therapies for age-related diseases. The company is based in Menlo Park, California, and was established in 2007. Cohbar Inc's mission is to enhance human health and extend lifespan by leveraging breakthroughs in science and technology. The company's unique approach involves developing peptide-based therapeutics that target mitochondria, the powerhouses of our cells.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com